IBBvsVXF

iShares Biotechnology ETF or Vanguard Extended Market ETF, side by side from their own SEC filings. 7.6% of their stock holdings are the same at the same weight, across 156 stocks in both. VXF costs 0.05% a year against 0.44% for IBB, $39 a year less on $10,000. Over the last twelve months IBB returned +50.6% and VXF +29.1%.

7.6%of the two portfolios is the same stocks at the same weight
IBB50% in stocks the other holds too
VXF7.6% in stocks the other holds too
stocks in bothstocks only in that fundbonds, cash and unmatched shares

The two funds

From each fund's latest N-PORT filing and its prospectus.

IBBVXFYearly cost0.44%0.05%Net assets$9.1B$97.7BPositions2523,379Last 12 months+50.6%+29.1%3 years, a year+14.7%+19.7%5 years, a year+3.3%+6.7%Largest holdingBlackRock 12.0%Vanguard 3.7%Main sectorHealthcare 97%Technology 19%Holdings as ofJun 30, 2026Jun 30, 2026

Returns are total returns with dividends reinvested, from the funds’ own monthly figures; “(price)” marks a fund whose filing record is younger than a year, whose twelve months are its price change. The stronger figure in each row is set in bold. Past returns say what happened, not what will.

Growth of $100

Both funds from July 2019, the first month both report, dividends reinvested.

IBB$177VXF$226
July 2019June 2026

More comparisons

From each fund’s Form N-PORT (IBB: June 2026, VXF: June 2026) and prospectus, via the SEC’s public data sets. Overlap counts only the stocks we can match to a listing: stock by stock, the smaller of the two weights, added up.